NCT07301203

Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Single and Multiple Doses of CPD704 Inhalation Suspension in Healthy Chinese Adult Subjects.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Beijing Tide Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects.

Detailed description

This study is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension administered via nebulization in healthy Chinese adult subjects.

Conditions

• Healthy
• Healthy Participants

Interventions

Type	Name	Description
DRUG	CPD704 Inhalation Suspension	This trial employs standard jet nebulizers (air-compression nebulizers) for oral inhalation administration。
OTHER	CPD704 placebo	The placebo is administered via standard jet nebulizer (air-compression nebulizer) for oral inhalation

Timeline

• Start date: 2025-10-21
• Primary completion: 2026-06-08
• Completion: 2026-07-18
• First posted: 2025-12-24
• Last updated: 2025-12-24

Locations

1 site across 1 country: China